| Event-free survival with pembrolizumab in early triple-negative breast cancer P Schmid, J Cortes, R Dent, L Pusztai, H McArthur, S Kümmel, J Bergh, ... New England Journal of Medicine 386 (6), 556-567, 2022 | 677 | 2022 |
| CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti‐VEGF treatment or docetaxel in a transgenic mouse model S Hassan, M Buchanan, K Jahan, A Aguilar‐Mahecha, L Gaboury, ... International Journal of Cancer 129 (1), 225-232, 2011 | 155 | 2011 |
| An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer A Mamo, L Cavallone, S Tuzmen, C Chabot, C Ferrario, S Hassan, ... Oncogene 31 (16), 2090-2100, 2012 | 151 | 2012 |
| Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer MA Déry, J Jodoin, J Ursini-Siegel, O Aleynikova, C Ferrario, S Hassan, ... Breast cancer research 15 (2), 1-19, 2013 | 85 | 2013 |
| Tissue microarrays: emerging standard for biomarker validation S Hassan, C Ferrario, A Mamo, M Basik Current opinion in biotechnology 19 (1), 19-25, 2008 | 85 | 2008 |
| Plasma Stromal Cell–Derived Factor-1: Host Derived Marker Predictive of Distant Metastasis in Breast Cancer S Hassan, A Baccarelli, O Salvucci, M Basik Clinical Cancer Research 14 (2), 446-454, 2008 | 77 | 2008 |
| The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer S Hassan, C Ferrario, U Saragovi, L Quenneville, L Gaboury, A Baccarelli, ... The American journal of pathology 175 (1), 66-73, 2009 | 73 | 2009 |
| Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers S Hamel, A Bouchard, C Ferrario, S Hassan, A Aguilar-Mahecha, ... Breast cancer research and treatment 120 (1), 47-57, 2010 | 63 | 2010 |
| Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer L Cavallone, A Aguilar-Mahecha, J Lafleur, S Brousse, M Aldamry, ... Scientific Reports 10 (1), 14704, 2020 | 55 | 2020 |
| The estrogen receptor cofactor SPEN functions as a tumor suppressor and candidate biomarker of drug responsiveness in hormone-dependent breast cancers S Légaré, L Cavallone, A Mamo, C Chabot, I Sirois, A Magliocco, ... Cancer research 75 (20), 4351-4363, 2015 | 55 | 2015 |
| Microarrays as validation strategies in clinical samples: tissue and protein microarrays A Aguilar-Mahecha, S Hassan, C Ferrario, M Basik Omics: a journal of integrative biology 10 (3), 311-326, 2006 | 47 | 2006 |
| Translating the role of PARP inhibitors in triple-negative breast cancer M Beniey, T Haque, S Hassan Oncoscience 6 (1-2), 287, 2019 | 34 | 2019 |
| Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer S Hassan, A Esch, T Liby, JW Gray, LM Heiser Molecular cancer therapeutics 16 (12), 2892-2901, 2017 | 33 | 2017 |
| Clinical features and outcomes of 20 patients with abdominopelvic desmoplastic small round cell tumor FA Angarita, S Hassan, AJ Cannell, BC Dickson, RA Gladdy, CJ Swallow, ... European Journal of Surgical Oncology (EJSO) 43 (2), 423-431, 2017 | 25 | 2017 |
| Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease S Hassan, TM Petrella, T Zhang, S Kamel-Reid, F Nordio, A Baccarelli, ... Annals of surgical oncology 22 (6), 1950-1958, 2015 | 20 | 2015 |
| The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience M Yordanova, S Hassan Current Oncology 29 (3), 2008-2020, 2022 | 9 | 2022 |
| Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer M Yordanova, A Hubert, S Hassan Pharmaceuticals 14 (12), 1270, 2021 | 6 | 2021 |
| Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41 P Rastogi, G Tang, S Hassan, CE Geyer Jr, CA Azar, GC Magrinat, ... Breast Cancer Research and Treatment 199 (2), 243-252, 2023 | 4 | 2023 |
| Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer M Beniey, A Hubert, T Haque, AK Cotte, N Béchir, X Zhang, D Tran-Thanh, ... British Journal of Cancer 128 (10), 1964-1975, 2023 | 4 | 2023 |
| Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. SN Hassan, A Esch, L Heiser, JW Gray ASCO Annual Meeting Proceedings 33 (28_suppl), 125, 2015 | 4 | 2015 |
